PT2152880E - Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos - Google Patents
Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos Download PDFInfo
- Publication number
- PT2152880E PT2152880E PT08769934T PT08769934T PT2152880E PT 2152880 E PT2152880 E PT 2152880E PT 08769934 T PT08769934 T PT 08769934T PT 08769934 T PT08769934 T PT 08769934T PT 2152880 E PT2152880 E PT 2152880E
- Authority
- PT
- Portugal
- Prior art keywords
- locus
- meganuclease
- transgenic animal
- artificial
- endogenous
- Prior art date
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 209
- 238000000034 method Methods 0.000 title claims abstract description 98
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 77
- 102000018358 immunoglobulin Human genes 0.000 title claims description 77
- 108090000623 proteins and genes Proteins 0.000 title claims description 75
- 238000004519 manufacturing process Methods 0.000 title claims description 30
- 229940072221 immunoglobulins Drugs 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 10
- 230000005764 inhibitory process Effects 0.000 title description 2
- 241001465754 Metazoa Species 0.000 claims abstract description 245
- 210000004602 germ cell Anatomy 0.000 claims description 152
- 210000004027 cell Anatomy 0.000 claims description 84
- 108020004707 nucleic acids Proteins 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 44
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 210000000287 oocyte Anatomy 0.000 claims description 43
- 230000008707 rearrangement Effects 0.000 claims description 28
- 230000002068 genetic effect Effects 0.000 claims description 27
- 230000002163 immunogen Effects 0.000 claims description 25
- 210000001161 mammalian embryo Anatomy 0.000 claims description 25
- 230000001939 inductive effect Effects 0.000 claims description 19
- 101150117115 V gene Proteins 0.000 claims description 16
- 101150008942 J gene Proteins 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 14
- 210000004408 hybridoma Anatomy 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 10
- 101150111062 C gene Proteins 0.000 claims description 6
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 5
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 2
- 238000001212 derivatisation Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 28
- 239000013598 vector Substances 0.000 description 21
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 108700019146 Transgenes Proteins 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 210000002257 embryonic structure Anatomy 0.000 description 12
- 108010042407 Endonucleases Proteins 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000006801 homologous recombination Effects 0.000 description 11
- 238000002744 homologous recombination Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 10
- 102000004533 Endonucleases Human genes 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 101150097493 D gene Proteins 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 241000286209 Phasianidae Species 0.000 description 6
- 230000009849 deactivation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 241000272517 Anseriformes Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 101710185494 Zinc finger protein Proteins 0.000 description 4
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 230000007018 DNA scission Effects 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000269420 Bufonidae Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 241000428199 Mustelinae Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 102000036072 fibronectin binding proteins Human genes 0.000 description 2
- 108091010988 fibronectin binding proteins Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 101150118163 h gene Proteins 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002406 microsurgery Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 101150098879 43 gene Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100166834 Mus musculus Cp gene Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007720 allelic exclusion Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 102000021124 collagen binding proteins Human genes 0.000 description 1
- 108091011142 collagen binding proteins Proteins 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8775—Murine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94161907P | 2007-06-01 | 2007-06-01 | |
| US4432408P | 2008-04-11 | 2008-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2152880E true PT2152880E (pt) | 2011-12-15 |
Family
ID=40111008
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08769934T PT2152880E (pt) | 2007-06-01 | 2008-05-30 | Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos |
| PT121877872T PT2602323T (pt) | 2007-06-01 | 2008-05-30 | Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos |
| PT111617759T PT2336329E (pt) | 2007-06-01 | 2008-05-30 | Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT121877872T PT2602323T (pt) | 2007-06-01 | 2008-05-30 | Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos |
| PT111617759T PT2336329E (pt) | 2007-06-01 | 2008-05-30 | Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US8703485B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3382022A1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP5823690B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR101661357B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101784664B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE522611T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008259939B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3054224A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1120383T1 (cg-RX-API-DMAC7.html) |
| DK (3) | DK2602323T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2393826T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20180506T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE037302T2 (cg-RX-API-DMAC7.html) |
| IL (2) | IL202302A (cg-RX-API-DMAC7.html) |
| LT (1) | LT2602323T (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ581396A (cg-RX-API-DMAC7.html) |
| PL (3) | PL2336329T3 (cg-RX-API-DMAC7.html) |
| PT (3) | PT2152880E (cg-RX-API-DMAC7.html) |
| SG (2) | SG182144A1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2602323T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008151081A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12016313B2 (en) | 2017-01-19 | 2024-06-25 | Omniab Operations, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2440990T5 (es) | 2004-07-22 | 2022-10-25 | Univ Erasmus Med Ct Rotterdam | Moléculas de unión |
| SI2602323T1 (en) * | 2007-06-01 | 2018-05-31 | Open Monoclonal Technology, Inc. | Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies |
| CA2736336A1 (en) * | 2008-09-08 | 2010-03-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof |
| DK2346994T3 (da) * | 2008-09-30 | 2022-02-28 | Ablexis Llc | Knock-in-mus til fremstilling af kimære antistoffer |
| CA2745031C (en) * | 2008-12-04 | 2018-08-14 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
| RU2011129459A (ru) | 2008-12-18 | 2013-01-27 | Эрасмус Юниверсити Медикал Сентр Роттердам | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение |
| GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| EP2517556B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| DK2509409T3 (en) | 2009-12-10 | 2016-11-14 | Regeneron Pharma | MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES |
| WO2011097603A1 (en) | 2010-02-08 | 2011-08-11 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| KR102004106B1 (ko) | 2010-03-31 | 2019-07-25 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
| SG186238A1 (en) * | 2010-06-17 | 2013-01-30 | Kymab Ltd | Animal models and therapeutic molecules |
| DK2597945T3 (da) | 2010-07-26 | 2020-09-21 | Trianni Inc | Transgene dyr og fremgangsmåder til anvendelse deraf |
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| RS55495B1 (sr) | 2010-08-02 | 2017-04-28 | Regeneron Pharma | Miševi koji stvaraju vezujuće proteine koji sadrže vl domene |
| KR101938343B1 (ko) | 2011-03-09 | 2019-01-14 | 셀 시그널링 테크놀러지, 인크. | 모노클로날 항체를 생성하는 방법 및 시약 |
| SG194089A1 (en) * | 2011-04-27 | 2013-11-29 | Amyris Inc | Methods for genomic modification |
| SI3865581T1 (sl) | 2011-08-05 | 2024-12-31 | Regeneron Pharmaceuticals, Inc. | Miši s humanizirano univerzalno lahko verigo |
| CA2846319A1 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| EP2758529B1 (en) | 2011-09-21 | 2019-03-20 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
| EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| SG10202010120XA (en) | 2011-10-17 | 2020-11-27 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| PT2847335T (pt) | 2012-04-25 | 2018-09-28 | Regeneron Pharma | Alvejamento mediado por nuclease com vetores de alvejamento grandes |
| CN104540383B (zh) | 2012-06-12 | 2017-08-29 | 瑞泽恩制药公司 | 具有受限制的免疫球蛋白重链基因座的人源化非人动物 |
| MX2014015204A (es) * | 2012-06-12 | 2015-08-07 | Genentech Inc | Metodos y composiciones para generar alelos con inactivacion condicional. |
| ES2963516T3 (es) | 2012-12-14 | 2024-03-27 | Omniab Inc | Polinucleótidos que codifican anticuerpos de roedores con idiotipos humanos y animales que los contienen |
| WO2014130690A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| US9980470B2 (en) | 2013-03-14 | 2018-05-29 | Erasmus University Medical Center | Antibody production |
| US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
| WO2014172458A1 (en) * | 2013-04-16 | 2014-10-23 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| ES2993142T3 (en) | 2013-10-01 | 2024-12-23 | Kymab Ltd | Animal models and therapeutic molecules |
| US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
| ES2872475T3 (es) | 2014-03-21 | 2021-11-02 | Regeneron Pharma | Animales no humanos que producen proteínas de unión de dominio único |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| US10336825B2 (en) | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
| PT3137504T (pt) | 2014-04-30 | 2023-08-18 | Hanall Biopharma Co Ltd | Anticorpo que se liga a fcrn para tratar doenças autoimunes |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| LT3152312T (lt) | 2014-06-06 | 2020-04-27 | Regeneron Pharmaceuticals, Inc. | Tikslinio lokuso modifikavimo būdai ir kompozicijos |
| EP3461885B1 (en) | 2014-06-26 | 2021-10-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| EP3174902B1 (en) | 2014-08-01 | 2019-04-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | An anti-cd45rc antibody for use as drug |
| HUE044907T2 (hu) | 2014-11-21 | 2019-11-28 | Regeneron Pharma | Módszerek és készítmények célzott genetikai módosításhoz, párosított mutató RNS-ek használatával |
| NZ732895A (en) | 2014-12-19 | 2022-05-27 | Regeneron Pharma | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| JP2018508224A (ja) | 2015-03-19 | 2018-03-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗原を結合する軽鎖可変領域を選択する非ヒト動物 |
| WO2016161446A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| WO2017035252A1 (en) * | 2015-08-24 | 2017-03-02 | Trianni, Inc. | Enhanced production of immunoglobulins |
| US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| US11053288B2 (en) | 2016-02-04 | 2021-07-06 | Trianni, Inc. | Enhanced production of immunoglobulins |
| EP3462853B1 (en) | 2016-06-03 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
| US12495776B2 (en) | 2016-08-24 | 2025-12-16 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| SI4050034T1 (sl) | 2016-09-14 | 2024-07-31 | Teneoone, Inc. | Protitelesa, ki se vežejo na CD3 |
| EP3515950A4 (en) | 2016-09-20 | 2020-10-28 | Wuxi Biologics Ireland Limited. | NEW ANTI-PCSK9 ANTIBODIES |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio Inc | anticorpos apenas de cadeia pesada anti-bcma |
| EP4585261A3 (en) | 2016-12-21 | 2025-08-13 | Cephalon LLC | Antibodies that specifically bind to human il-15 and uses thereof |
| IL312322A (en) | 2017-06-20 | 2024-06-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
| MX2019015563A (es) | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anticuerpos anti-bcma unicamente de cadena pesada. |
| US11021540B2 (en) | 2017-09-07 | 2021-06-01 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
| CA3075399A1 (en) | 2017-09-13 | 2019-03-21 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
| JP7486421B2 (ja) | 2017-12-22 | 2024-05-17 | テネオバイオ， インコーポレイテッド | Ｃｄ２２に結合する重鎖抗体 |
| KR20250034193A (ko) | 2017-12-27 | 2025-03-10 | 테네오바이오, 인코포레이티드 | Cd3-델타/엡실론 이형이량체 특이적 항체 |
| HUE070158T2 (hu) | 2018-03-24 | 2025-05-28 | Regeneron Pharma | Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk |
| US12102070B2 (en) * | 2018-06-13 | 2024-10-01 | Crystal Bioscience Inc. | Camelization of a human variable domain by gene conversion |
| JP7515410B2 (ja) * | 2018-06-13 | 2024-07-12 | クリスタル バイオサイエンス インコーポレイテッド | 複数のジスルフィド架橋によって安定化され、遺伝子変換によって多様化された長いｃｄｒ－ｈ３ｓで抗体を作製するトランスジェニックニワトリ |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| WO2020018922A1 (en) | 2018-07-20 | 2020-01-23 | Teneobio, Inc. | Heavy chain antibodies binding to cd19 |
| SG11202100663VA (en) | 2018-08-01 | 2021-02-25 | Cephalon Inc | Anti-cxcr2 antibodies and uses thereof |
| EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
| BR112021014574A2 (pt) | 2019-01-23 | 2021-10-05 | Encefa | Competidores cd31 e usos dos mesmos |
| EP3927832A4 (en) | 2019-02-18 | 2022-11-30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS |
| CR20210500A (es) | 2019-04-05 | 2021-11-05 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al psma |
| JP2022538733A (ja) | 2019-05-20 | 2022-09-06 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 新規抗ｃｄ２５抗体 |
| UA128906C2 (uk) | 2019-06-14 | 2024-11-20 | Тенеобіо, Інк. | Поліспецифічні антитіла, що містять тільки важкі ланцюги, які зв'язуються з cd22 та cd3 |
| CA3155930A1 (en) | 2019-09-27 | 2021-04-01 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| EP4069722A1 (en) | 2019-12-02 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| CN115894703A (zh) | 2020-04-29 | 2023-04-04 | 特尼奥生物股份有限公司 | 具有经修饰重链恒定区的多特异性重链抗体 |
| CN115667532A (zh) | 2020-06-02 | 2023-01-31 | 百奥赛图(北京)医药科技股份有限公司 | 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物 |
| IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
| US20240002521A1 (en) | 2020-11-20 | 2024-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| AU2021380966A1 (en) | 2020-11-20 | 2023-06-22 | Alderaan Biotechnology | Anti-cd25 antibodies |
| CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| EP4559939A3 (en) | 2020-12-23 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses therof |
| AU2023212994A1 (en) | 2022-01-28 | 2024-08-08 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
| EP4490188A1 (en) | 2022-03-09 | 2025-01-15 | Alderaan Biotechnology | Anti-cd160 transmembrane isoform antibodies |
| CA3254741A1 (en) | 2022-05-30 | 2023-12-07 | Hanall Biopharma Co., Ltd. | ANTI-FCRN ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF FCRN EXHIBITING IMPROVED STABILITY |
| WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
| WO2025191147A1 (en) | 2024-03-14 | 2025-09-18 | Synabs | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4977081A (en) | 1987-05-04 | 1990-12-11 | Adi Diagnostics, Inc. | Stable rabbit-mouse hybridomas and secretion products thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) * | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| CA2066433A1 (en) | 1990-07-10 | 1992-01-11 | Haruo Matsuda | Chicken-specific immunoglobulin g-producing hybridoma |
| AU664976B2 (en) | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE4119749A1 (de) | 1991-06-15 | 1992-12-17 | Claas Ohg | Verfahren zum entholzen von flachs und flachsaufbereitungsmaschine zur durchfuehrung dieses verfahrens |
| ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| EP0583980A1 (en) | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Method for generating monoclonal antibodies from rabbits |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| PT1589107E (pt) | 1992-08-21 | 2010-03-29 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5795974A (en) | 1993-12-10 | 1998-08-18 | University Of Utah Research Foundation | Mycoplasma arthritidis superantigen |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU7326796A (en) | 1995-10-30 | 1997-05-22 | Spectral Diagnostics Inc. | Stable chicken b-cell line and method of use thereof |
| US5716081A (en) | 1996-03-11 | 1998-02-10 | Automotive Products (Usa), Inc. | Spring clip for quick connect coupling |
| EP2305027B1 (en) * | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| WO2000039316A1 (en) * | 1998-12-31 | 2000-07-06 | The J. David Gladstone Institutes | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
| US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
| NZ521696A (en) * | 2000-04-24 | 2004-06-25 | Wyeth Corp | Transgenic animal models for diseases that are regulated by G-protein signalling |
| EP1311530A4 (en) * | 2000-08-03 | 2004-10-06 | Wim-Van Schooten | PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA03004793A (es) * | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| JP2005502341A (ja) | 2001-08-20 | 2005-01-27 | メルク エンド カムパニー インコーポレーテッド | Ｂ１ブラジキニン受容体タンパク質を調節するための動物モデルとしてのトランスジェニックげっ歯類 |
| EP1427828B1 (en) * | 2001-09-14 | 2010-04-28 | Cellectis | Random integration of a polynucleotide after in vivo linearization |
| US7435871B2 (en) | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
| EP1485475B2 (en) | 2002-03-15 | 2017-09-20 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| EP2368982A3 (en) * | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| CA2514517A1 (en) * | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| US20040158880A1 (en) * | 2003-02-05 | 2004-08-12 | Roland Buelow | Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| RS20050934A (sr) * | 2003-06-16 | 2008-04-04 | Celltech R. & D. Inc., | Antitela specifična za sklerostin i metode za povećanje mineralizacije kostiju |
| CN103205436B (zh) * | 2003-07-15 | 2016-05-25 | 人类多克隆治疗公司 | 人源化免疫球蛋白基因座 |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US20050153392A1 (en) * | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
| WO2005038001A2 (en) * | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
| US8137966B2 (en) | 2004-03-04 | 2012-03-20 | Dainippon Sumitomo Pharma Co., Ltd. | Rat embryonic stem cell |
| ES2440990T5 (es) | 2004-07-22 | 2022-10-25 | Univ Erasmus Med Ct Rotterdam | Moléculas de unión |
| WO2006047367A2 (en) * | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglubolin expression in non-human transgenic animals |
| KR20070072608A (ko) * | 2004-10-22 | 2007-07-04 | 레비비코르 인코포레이션 | 유전자 변형된 면역계를 가지는 유제류 |
| EP1854473A1 (en) | 2005-03-03 | 2007-11-14 | Takeda Pharmaceutical Company Limited | Preventive/therapeutic agent for cancer |
| WO2006097854A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | Heterodimeric meganucleases and use thereof |
| WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| US7491866B2 (en) | 2005-11-09 | 2009-02-17 | Board Of Regents University Of Texas System | Transgenic rats and spermatogonial stem cells |
| JP5184374B2 (ja) | 2006-01-25 | 2013-04-17 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 対立遺伝子排除 |
| EP2003960B1 (en) | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| SI2602323T1 (en) * | 2007-06-01 | 2018-05-31 | Open Monoclonal Technology, Inc. | Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies |
| WO2014130690A1 (en) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
-
2008
- 2008-05-30 SI SI200831937T patent/SI2602323T1/en unknown
- 2008-05-30 ES ES11161775T patent/ES2393826T3/es active Active
- 2008-05-30 SG SG2012039913A patent/SG182144A1/en unknown
- 2008-05-30 KR KR1020097024974A patent/KR101661357B1/ko active Active
- 2008-05-30 LT LTEP12187787.2T patent/LT2602323T/lt unknown
- 2008-05-30 EP EP18158882.3A patent/EP3382022A1/en not_active Withdrawn
- 2008-05-30 SG SG10201509853UA patent/SG10201509853UA/en unknown
- 2008-05-30 PL PL11161775T patent/PL2336329T3/pl unknown
- 2008-05-30 CA CA3054224A patent/CA3054224A1/en active Pending
- 2008-05-30 DK DK12187787.2T patent/DK2602323T3/en active
- 2008-05-30 KR KR1020177002729A patent/KR101886610B1/ko active Active
- 2008-05-30 CA CA2688834A patent/CA2688834C/en active Active
- 2008-05-30 CN CN2008801012988A patent/CN101784664B/zh active Active
- 2008-05-30 DK DK08769934.4T patent/DK2152880T3/da active
- 2008-05-30 PL PL08769934T patent/PL2152880T3/pl unknown
- 2008-05-30 EP EP12187787.2A patent/EP2602323B1/en active Active
- 2008-05-30 HU HUE12187787A patent/HUE037302T2/hu unknown
- 2008-05-30 NZ NZ581396A patent/NZ581396A/en unknown
- 2008-05-30 US US12/130,818 patent/US8703485B2/en active Active
- 2008-05-30 PT PT08769934T patent/PT2152880E/pt unknown
- 2008-05-30 ES ES12187787.2T patent/ES2664218T3/es active Active
- 2008-05-30 EP EP11161775A patent/EP2336329B8/en active Active
- 2008-05-30 AT AT08769934T patent/ATE522611T1/de active
- 2008-05-30 JP JP2010510537A patent/JP5823690B2/ja active Active
- 2008-05-30 PT PT121877872T patent/PT2602323T/pt unknown
- 2008-05-30 AU AU2008259939A patent/AU2008259939B2/en active Active
- 2008-05-30 EP EP08769934A patent/EP2152880B1/en active Active
- 2008-05-30 WO PCT/US2008/065419 patent/WO2008151081A1/en not_active Ceased
- 2008-05-30 KR KR1020157022196A patent/KR101703299B1/ko active Active
- 2008-05-30 DK DK11161775.9T patent/DK2336329T3/da active
- 2008-05-30 PT PT111617759T patent/PT2336329E/pt unknown
- 2008-05-30 KR KR1020187022408A patent/KR102096731B1/ko active Active
- 2008-05-30 ES ES08769934T patent/ES2372718T3/es active Active
- 2008-05-30 PL PL12187787T patent/PL2602323T3/pl unknown
-
2009
- 2009-11-24 IL IL202302A patent/IL202302A/en active IP Right Grant
-
2010
- 2010-02-05 US US12/701,464 patent/US8907157B2/en active Active
-
2011
- 2011-07-27 US US13/192,407 patent/US9388233B2/en active Active
-
2012
- 2012-06-06 IL IL220209A patent/IL220209A/en active IP Right Grant
-
2013
- 2013-10-11 JP JP2013213996A patent/JP2014027947A/ja active Pending
-
2015
- 2015-07-30 JP JP2015150597A patent/JP6220827B2/ja active Active
-
2016
- 2016-07-08 US US15/206,063 patent/US10072069B2/en active Active
-
2017
- 2017-09-29 JP JP2017190442A patent/JP6712254B2/ja active Active
-
2018
- 2018-03-27 CY CY20181100345T patent/CY1120383T1/el unknown
- 2018-03-27 HR HRP20180506TT patent/HRP20180506T1/hr unknown
- 2018-09-10 US US16/127,065 patent/US20190169270A1/en not_active Abandoned
-
2020
- 2020-05-27 JP JP2020092210A patent/JP2020125360A/ja active Pending
- 2020-12-22 US US17/131,164 patent/US20210253673A1/en active Pending
-
2022
- 2022-06-23 JP JP2022101081A patent/JP2022118217A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12016313B2 (en) | 2017-01-19 | 2024-06-25 | Omniab Operations, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2152880E (pt) | Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos | |
| JP2010529042A6 (ja) | 内在性免疫グロブリン遺伝子を阻害し、そして、トランスジェニック・ヒト・イディオタイプ抗体を製造するための組成物及び方法 | |
| HK1261736A1 (en) | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies | |
| HK1186493A (en) | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies | |
| HK1135138B (en) | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies | |
| HK1186493B (en) | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |